Relugolix reduces leiomyoma extracellular matrix production via the transforming growth factor-beta pathway
- 28 December 2024
- journal article
- Published by Elsevier in F&S Science
- Vol. 6 (2) , 213-220
Abstract
No abstract availableKeywords
Funding Information
- Uniformed Services University of the Health Sciences
This publication has 45 references indexed in Scilit:
- Wnt/β-catenin signaling pathway in uterine leiomyoma: role in tumor biology and targeting opportunitiesMolecular and Cellular Biochemistry, 2021
- Leiomyoma fibrosis inhibited by liarozole, a retinoic acid metabolic blocking agentFertility and Sterility, 2012
- Gonadotropin-releasing hormone (GnRH) agonist leuprolide acetate and GnRH antagonist cetrorelix acetate directly inhibit leiomyoma extracellular matrix productionFertility and Sterility, 2012
- Efficacy and tolerability of CDB-2914 treatment for symptomatic uterine fibroids: a randomized, double-blind, placebo-controlled, phase IIb studyFertility and Sterility, 2011
- Myometrial cells undergo fibrotic transformation under the influence of transforming growth factor β-3Fertility and Sterility, 2010
- Human myometrium and leiomyomas express gonadotropin-releasing hormone 2 and gonadotropin-releasing hormone 2 receptorFertility and Sterility, 2007
- Novel method to characterize primary cultures of leiomyoma and myometrium with the use of confirmatory biomarker gene arraysFertility and Sterility, 2007
- Transforming growth factor-β signaling through the Smad proteins: Role in systemic sclerosisAutoimmunity Reviews, 2006
- Comparative ultrastructure of collagen fibrils in uterine leiomyomas and normal myometriumFertility and Sterility, 2004
- Liarozole fumarate inhibits the metabolism of 4-keto-all-trans-retinoic acidBiochemical Pharmacology, 1994